Skip to content

Comparison of Emla cream and Cold on the injection site pain in Enoxaparin

Comparison of Emla cream and Cold compress on the injection site pain intensity in Enoxaparin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013100914956N1
Enrollment
53
Registered
2014-01-22
Start date
2013-12-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injection pain. Acute pain

Interventions

Intervention 1: First method: Injection Enoxaparin without interference(Subcutaneous injection of Enoxaparin-Na for 10 seconds in the right or left side of abdomen). Intervention 2: Second method:In t
Prevention
First method: Injection Enoxaparin without interference(Subcutaneous injection of Enoxaparin-Na for 10 seconds in the right or left side of abdomen)
Second method:In this method 1/5 gr Emla cream is placed on the injection site with holder dressing 60 minute before the injection and dressing is removed after the one hour, then area is cleaned and
Third method: In this method, a piece of ice the size of 4*2*2 Cm is placed inside the latex gloves and is placed on the injection site 5 minute before the injection

Sponsors

Shahid Sadoughi University of Medical Sciences Yazd, School of Nursing & Midwifery
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 18-65 years old; full consciousness; ability to communicate; not a severe pain in other areas; no history of prescribed Enoxaparin; no scarring and lesions at the injection site and no history of allergy to lidocaine & Prilocain. Exclusion criteria: loss of consciousness; sensorimotor disorders; injection of other drug in the abdomen during the study, and two days before the study; prescription of narcotic and non-narcotic analgesics 2 hours before injection; allergy to EMLA cream; the development of diabetic neuropathy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Injection pain. Timepoint: Immediate,5 &10 minute after injection. Method of measurement: Using the VAS scale & record severe pain intensity.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Zeighamian

Shahid Sadoughi University of Medical Sciences Yazd, School of Nursing & M

somayehz196@gmail.com+98 35 1824 1751

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026